The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 24, 2018
Filed:
Jan. 06, 2015
Applicant:
Oklahoma Medical Research Foundation, Oklahoma City, OK (US);
Inventors:
Rheal Towner, Piedmont, OK (US);
Jonathan Wren, Norman, OK (US);
Assignee:
OKLAHOMA MEDICAL RESEARCH FOUNDATION, Oklahoma City, OK (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/22 (2006.01); C07K 16/18 (2006.01); A61K 39/395 (2006.01); C07K 16/30 (2006.01); C07K 16/24 (2006.01); C07K 16/28 (2006.01); G01N 33/574 (2006.01); A61K 45/06 (2006.01); C12Q 1/6886 (2018.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/3053 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); C07K 16/18 (2013.01); C07K 16/22 (2013.01); C07K 16/24 (2013.01); C07K 16/28 (2013.01); C07K 16/2803 (2013.01); C07K 16/2863 (2013.01); C12Q 1/6886 (2013.01); G01N 33/57407 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/76 (2013.01); C12Q 2600/158 (2013.01); G01N 2333/47 (2013.01); G01N 2333/705 (2013.01);
Abstract
The present disclosure is directed to antibodies binding to ELTDI. Plexin-B2, Spondin-1, fibulin-1, LINGO I or SLIT3 and methods of using such antibodies to treat and/or diagnose gliomas. Thus, in accordance with the present disclosure, there is provided a method of inhibiting a glioma cell comprising contacting said glioma cell with a first antibody or antibody fragment that binds immunologically to ELTDI, Plexin-B2, Spondin-1 or SLIT3. The method may further comprise contacting said glioma cell with a second anti-cancer agent or treatment.